csDMARDs

Dose-Dependent ACR20 Response Rates in RA With Peficitinib

Dose-Dependent ACR20 Response Rates in RA With Peficitinib

By

Use of the JAK inhibitor peficitinib in combination with certain csDMARDs results in a dose-dependent ACR20 response rate in patients with RA over 12 weeks.

Sign Up for Free e-Newsletters